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Abstract
Background: The concept that a strong inflammatory response involving the full complement of cytokines and
other mediators is critical for unimpaired healing has been challenged by wound healing studies using transgenic
and knockout (KO) mice. The present study explored the effect of abrogation of the p40 subunit, which is shared
by the pro-inflammatory cytokines interleukin (IL)-12 and IL-23, on wound closure of excisional oral mucosal
wounds.
Methods: Double IL-12 and IL-23 KO mice and C57BL ⁄ 6J wildtype mice were wounded on the dorsal surface of
the tongue using a 2 mm biopsy punch. The degree of epithelialization was examined histologically. At specific
timepoints wounds were examined for cellular and molecular markers for inflammation and angiogenesis using
1) immunohistochemistry; 2) analysis of RNA expression; and 3) flow cytometric analysis.
Results: Compared to wild type controls, KO mice displayed enhanced healing, which was driven by a greater
influx of neutrophils and macrophages during the early stages of wound healing, and increased induction of
messenger RNA (mRNA) for endothelial derived neutrophil attractant (ENA78) chemokine and macrophage
inflammatory protein-2 alpha (MIP-2a). Increased mRNA for monocyte-attracting chemokines including monocyte
chemoattractant protein (MCP)-1 and MCP-3 was seen from day 1, together with higher levels of IL-1b and IL-6
within 24 hours after wounding. In addition, mRNA for vascular endothelial growth factor (VEGF)-A was
upregulated in KO mice within 2 hours after injury, and higher expression of this mediator was confirmed by
immunohistochemistry.
Conclusion: Overall, the accelerated oral mucosal wound healing seen in IL-12/IL-23p40 KO compared to wildtype
mice was associated with the early establishment of an inflammatory response and vascularization.
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Background
A wound undergoes three distinct stages which overlap in
time as it heals: inflammation, proliferation and remodel-
ing/tissue maturation. The characteristics of the inflamma-
tory response define the progress of a healing wound. For
example, diabetic ulcers and chronic pressure ulcers are
associated with persistent inflammation [1], while keloids
or scar formation is rarely seen in fetal wounds which
show a diminished inflammatory response [2]. Studies
using transgenic and knockout (KO) mice shed significant
light on the cellular and molecular mechanisms in wound
healing. For example, PU.1-knockout mice which are
deficient in neutrophils and macrophages show slightly
enhanced rates of re-epithelialization, enhanced angiogen-
esis, and an absence of fibrosis [3], with phagocytosis
being undertaken by fibroblasts. A cluster of genes
expressed after wounding has been linked with tissue
repair genes, and another with inflammation and its con-
sequences. The former provides the basic repertoire to
allow normal healing to occur, even in the absence of pro-
fessional phagocytes [4]. This gene cluster concept cast
doubts on the dogma that inflammation is mandatory for
repair after injury.
Wound healing studies in cytokine KO mice have
shown that both pro- and anti- inflammatory cytokines
influence the healing process. While IL-6 KO mice [5]
and IL-1 receptor antagonist (IL-1ra) KO mice [6] show
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tor p55 [7] or IFN-g show accelerated healing, most
likely by augmenting TGF-b1 mediated signalling path-
ways [8]. A recent study of wound healing in IL-10 KO
mice also showed accelerated wound healing [9]. IL-10
down-regulates several pro-inflammatory cytokines
including IL-1, IL-6, IL-12, IFN-g and TNF-a. IL-10
-/-
mice show accelerated re-epithelialization as well as
greater macrophage infiltration and enhanced wound
contraction compared to wild-type controls [9].
Dissecting the process of wound healing using other
well established cytokine KO mice such as IL12/IL-23p40
is of interest because it is shared by two inflammatory
cytokines, interleukin-12 (IL-12) and interleukin-23 (IL-
23). IL-12/IL-23p40 is produced primarily by activated
inflammatory cells such as macrophages, neutrophils and
dendritic cells as well as by keratinocytes and respiratory
epithelial cells [10-12]. The effects of IL-12 and IL-23 are
related but distinct. IL-12 promotes differentiation of
CD4+ naïve T cells to TH1 effector cells which stimulate
natural killer (NK) cells and CD8+ T cells to produce
IFN-g [11]. In contrast, IL-23 stimulation of naïve CD4+
T cells in conjunction with IL-1b gives rise to TH17 cells,
which secrete multiple cytokines including IL-17A, IL-
17F, IL-22, IL-26, IFN-g,I L - 6a n dT N F - a.T h e r ei sa l s o
evidence that the IL-23-17A axis is important in early
mucosal immune responses [13].
A potential role for IL-12 and IL-23 in wound heal-
ing is suggested by IL-12 having anti- angiogenic activ-
ity which is mediated through its effects on promoting
secretion of IFN-g [14], which in turn increases pro-
duction of IFN-g-inducible protein 10 (IP-10) a potent
inhibitor of angiogenesis which prevents formation of
new blood vessels [15-17]. The IL-12/IL-23p40 mole-
cule itself appears to be a natural antagonist to IL-12,
competitively binding to the IL-12b1 receptor [18,19].
The molecule also serves as a chemoattractant for
macrophages [20] and it promotes migration of acti-
vated dendritic cells [21]. Blockade of IL-12/IL-23p40
through its effects on IL-23 may also influence wound
healing by up-regulation of MMP-9 which has down-
stream effects on angiogenesis [22]. Despite the above
work, the basic question of whether inflammation is
beneficial or a hindrance in the wound repair process
remains, and use of p40 KO mice may provide further
insight into this. The present study uses an oral muco-
sal wound healing model based on excisional tongue
biopsies which follows wound healing events as in the
skin.
This study is the first to report that abrogation of the
IL-12/IL-23p40 molecule results in accelerated re-
epithelialization of wounds, and reveals that IL-12 and
IL-23 influence wound healing by modulating early
inflammatory responses and subsequent angiogenesis.
Methods
Animals
Specific pathogen-free female IL-12/IL-23p40
-/- mice and
their respective C57BL/6J controls 6-8 weeks of age were
used in these experiments. IL-12/IL-23p40
-/- mice raised
on C57BL/6J background [23] were obtained from the
Monash Institute of Reproduction and Development,
Monash University Melbourne Australia. Mice were bred
at Herston Medical Research Centre, Brisbane, Australia,
with regular polymerase chain reaction (PCR) based geno-
typing. Mice were housed in filter-top cages in a PC2 facil-
i t y ,a n dp r o v i d e df o o da n dw a t e rad libitum.A n i m a l
experiments were approved by the Animal Experimenta-
tion Ethics Committee of the University of Queensland,
and carried out in accordance with the National Health
and Medical Research Council’s Australian Code of Prac-
tice for the Care and Use of Animals for Scientific Pur-
poses, 1997.
Wound healing model
Under light general anesthesia, a wound was created using
a standard 2 mm diameter punch biopsy positioned along
the dorsal mid-line of the tongue, 3 mm from its anterior
tip. Animals were sacrificed at specific timepoints for: 1)
immunohistochemistry; 2) analysis of RNA expression;
and 3) flow cytometric analysis. In all cases, a 4 mm
punch biopsy was used to harvest the wound site so that
the wound was removed in toto. For analysis of RNA
expression, harvested wounds were stored immediately in
RNAlater
® (Ambion, Applied Biosystems, Austin, TX,
USA) and kept at -80°C. Samples harvested for histology
were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) for a minimum of 2 days, then bisected and
embedded in paraffin. Serial sections from the central por-
tion of the wounds were used for histological analysis. For
flow cytometric analysis, tissues were placed into RPMI
1640 medium (Invitrogen; Mulgrave, VIC, Australia) con-
taining antibiotics/antimycotics (Ab/Am; Gibco
®-Invitro-
gen, Mulgrave, VIC, Australia) and processed immediately.
Histology
For each strain of mice and for each time point, 10 mice
were wounded and wounds were harvested on day 0
(unwounded) and at 1, 4, 7 and 10 days after wounding.
Serial sections from the central portion of the wound were
stained with haematoxylin and eosin, and the extent of
wound closure determined. A wound was defined as com-
pletely healed/closed when all central serial sections
demonstrated an intact superficial epithelial layer over the
wound area.
Histochemistry
Harvested wounds (n = 3) from IL-12/IL-23p40
-/- mice
and C57BL/6J controls were collected at day zero and at
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central wound area were used for analysis. Antigen
retrieval from the fixed tissues was undertaken using
microwave treatment in 0.01 M sodium citrate buffer.
Prior to the first layer reagent, sections were treated
with Peroxidazed 1 (Biocare Medical, LLC; Concord,
CA) for 10 minutes to block endogenous peroxidise
activity, and then incubated with normal donkey serum
(5%) for 20 minutes to stop non-specific binding. The
first layer anti-mouse antibodies were applied at pre-
determined optimal dilutions overnight. Markers for
neutrophils (AbD, Serotec, Oxford, UK), macrophages
(M3/84) (BD Pharmingen, Franklin Lakes, NJ, USA),
CD31 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and Factor VIII related antigen (Zymed Laboratories,
San Francisco, CA) were used. The secondary antibody
(SuperPicture Broad Spectrum, Invitrogen, Mulgrave,
VIC, Australia) was then applied and incubated for
1 hour. For visualization, the Vector NovaRed Substrate
Kit (Vector Laboratories, Burlingame, CA) was used. Sec-
tions were counterstained with haematoxylin prior to
mounting. For Factor VIII staining, trypsin digestion
(Zymed Digest-All, Zymed Laboratories Inc., San Fran-
cisco, US) was performed for 1 hour at room temperature
before applying the primary antibody. The slides were
then scanned using Aperio Scanner (Aperio, California,
USA) and the digital slides stored for analysis. For each
specimen, equivalent fields were examined on serial sec-
tions, thus enabling comparisons to be made between
markers. In all cases, localization was assessed both quali-
tatively and quantitatively. The number of neutrophils
and macrophages was calculated as number of positive
cells counted in 10 high-power fields (× 400 magnifica-
tion) divided by 10 [24,42]. Anti-CD31 antibody was used
to localize areas of angiogenesis. This antibody stains cell
surfaces of monocytes, neutrophils, platelets and
endothelial cells, and has been used frequently as a mar-
ker of angiogenesis in a number of wound healing studies
[7,9,25,26]. Using Aperio ImageScope v10 software area
for CD31 and Factor VIII staining was measured. As pre-
viously described, CD31 positive areas within the wound
bed were measured and the percent vascularization was
calculated as: % CD31+ve area = (CD31+ve area/Total
wound bed area) × 100% [25]. Anti-Factor VIII, a marker
which is specific for endothelial cells, megakaryocytes
and platelets was used to confirm areas of angiogenesis.
The area of Factor VIII staining was calculated as % Fac-
tor VIII (Angiogenesis) = (Factor VIII+ve area/Total
wound bed area) × 100%.
Analysis of RNA expression
RNA was isolated from 2 mice per strain (IL-12/IL-
23p40
-/- m i c ea n dC 5 7 B L / 6 J )a tf o u rt i m e p o i n t s :d a y0
(unwounded), 2 hours, 1 day and 4 days after wounding,
from the 4mm biopsies using TRIZOL (Invitrogen, Mul-
grave, VIC, Australia) according to the manufacturer’s
instructions. To prevent amplification from genomic
DNA templates, total RNA was DNAse- treated using
DNA-free™(Ambion, Applied Biosystems, Austin, TX,
USA) according to the manufacturer’s instructions. RNA
concentration was determined by spectrophotometry
using the NanoDrop
® ND-1000 (Thermo Scientific,
Washington, USA), and the ratio of absorbance at 260
nm and 280 nm was used to assess the purity of the
sample. To check RNA integrity, total RNA was electro-
phoresed in 1.2% agarose gel. 28S and 18S rRNA served
as markers for RNA integrity.
cDNA was prepared using the “Superscript III” kit
(Invitrogen, Mulgrave, VIC, Australia)u s i n gr a n d o m
hexamers (Promega, Alexandria, NSW, Australia) from
3 μg of total RNA according to the manufacturer’s
instructions. mRNA for 84 genes involved in inflamma-
tion and immunity including IL-1B, IL-6, MCP-1, MCP-
2, Cxcl2 (MIP-2) and Cxcl5 (Ena-78) was quantified in
triplicate using the SuperArray RT
2Profiler™ PCR Array
(PAMM-073E) (SABioscience, Frederick, MD, USA). Fold
changes in expression of the genes of interest (GOI)
between samples were calculated using the software pro-
vided by the array manufacturer. The average of house-
keeping genes (HKG) including glucoronidase b-1
(Gusb), hypoxanthine guanine phosporibosyl tranferase
1 (Hprt1), heat shock protein 90 kDa a class B member
1 (Hprt1), glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) and Actin-b 1 (Actb) was used. The change in
Ct value was calculated as: Ct =C GOI
t − CAVG HKG
t .T h e
change for each gene across two groups was calculated
as: ΔΔCt =C t(group 1) - Ct(group2) where group 1 was
the control and group 2 the experimental group.
Following this, the fold-change for each gene from
group 1 to group 2 was calculated as 2(-ΔΔCt)w i t hp-
value of 0.05.
VEGF-a mRNA and the loading control 18S ribosomal
RNA (rRNA) were quantified on a 7900 Sequence Detec-
tion System in triplicate using SDS 2.2.3 software (Applied
Biosystems, Mulgrave, VIC, Australia). Reactions con-
tained SYBR green PCR master mix (Applied Biosystems,
Mulgrave, VIC, Australia),V E G F - a primer (F-cacgaca-
gaaggagagcaga, R-aagatgtccaccagggtctc, 100 nM) and 18S
(F-catttggagggcaagtctgg, R-tcccaagatccaactacgagc, 100 nM)
and the template diluted appropriately in distilled water.
Cycling conditions were 10 min @ 95°C, followed by 45
cycles of 15 sec @ 95°C and 1 min @ 59°C. Complemen-
tary DNA synthesis reactions conducted with no reverse
transcriptase were included to control for genomic DNA
contamination. Post-PCR melt analysis was conducted to
ensure that the quantified PCR products were pure and
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method (Applied Biosystems, Mulgrave, VIC, Australia)
was used to determine cytokine mRNA expression relative
to 18S rRNA, relative to unwounded wildtype. Fold
changes were calculated as mentioned above.
Flow cytometry
Six tissue samples were harvested and pooled for each
of IL-12/IL-23p40
-/- and C57BL/6J mice for the follow-
ing timepoints: day 0 (unwounded), 2 hours, 1 day,
4 days and 7 days after wounding. Tissues were homo-
genized and a single cell suspension prepared for flow
cytometry analysis as described previously [13]. Briefly,
tissues were placed in digestion medium [RPMI-1640
(Invitrogen, Mulgrave, VIC, Australia), 5% fetal calf
serum (FCS) (Gibco
®-Invitrogen, Invitrogen, Mulgrave,
VIC, Australia), Ab/Am (Gibco
®-Invitrogen, Mulgrave,
VIC, Australia),m o n e n s i n(eBioscience; San Diego, CA),
collagenase 1A (2 mg/mL; Sigma-Aldrich; Castle Hill,
NSW, Australia) and hyaluronidase (100U mL
-1; Sigma;
Castle Hill, NSW, Australia)] after being minced finely
using a scalpel blade. The samples were incubated in
digestion medium for 1.5 hours at 37°C in a shaking
water bath. Homogenates were then filtered through a
metal filter (250 μm) and the residue resuspended in
Cell-free Dissociation buffer (Life Technologies, Invitro-
gen, Mulgrave, VIC, Australia). The collected single cell
suspension was then diluted in RPMI-1640 containing
5% FCS, and cells then washed by centrifugation at 400
g for 3 min at 4°C. Cells were then resuspended in stain-
ing buffer [Flow Cytometry Staining Buffer (eBioscience;
San Diego, CA), containing 2% FCS (Gibco
®-Invitrogen,
Mulgrave, VIC, Australia)] to a final concentration of 4
×1 0
7 cells/mL.
For each immunofluorescence reaction, 2 × 10
6 cells
were incubated in 50 μl blocking buffer [1 μga n t i -
CD16/32 in 50 μl uL of staining buffer] for 10 minutes
on ice prior to incubation with monoclonal antibodies
(mAb) at pre-optimized dilutions as follows: fluorescein
isothiocyanate-conjugated (FITC) anti-F4/80 mAb
(macrophages) (1 μg per 2 × 10
6 cells, (eBioscience; San
Diego, CA), phycoerythrin (PE) conjugated anti-neutro-
phil mAb (20 μl per 2 ×10
6 cells, MCA771PE; Abd Sero-
tec, Raleigh, NC) and allophycocyanin (APC) conjugated
anti-CD31 mAb (1 μgp e r2×1 0
6 cells, (eBioscience;
San Diego, CA), for 30 minutes in the dark at 4°C. Sam-
ples were washed three times by centrifugation in PBS
at 400 g for 5 minutes at 4°C, then the cells resuspended
in Cell Dissociation Buffer (Life Technologies, Invitrogen,
Invitrogen, Mulgrave, VIC, Australia) for flow cytometric
analysis within 2 hours using an LSRII flow cytometer
(Becton Dickinson, North Ryde, Australia). Data collec-
tion was based on at least 10,000 events. Data were ana-
lyzed using FACSDiva software (V6.0; Becton Dickinson,
North Ryde, Australia). Gates were established using
unstained control samples including a 1:1 mixture of
cells from C57BL/6J mice and IL-12/IL-23p40
-/- mice.
Statistical Analysis
To test the null hypothesis that there was no difference
between healing in test and control mice, the log-rank
(Mantel-Cox) test was used. Differences in gene expres-
sion and in histological markers (inflammatory infiltrate,
vascularity and granulation tissue) were assessed using
the t- test.
Results
Accelerated rate of oral mucosal wound healing in IL-12
and IL-23 deficient mice
Histological analysis of healing wounds in IL-12/IL-
23p40
-/- and C57BL/6J showed an accelerated healing pat-
tern in the KO mice compared to WT mice (Log-rank
test, p = 0.002; Table 1), based on 10 mice (1 wound per
mice) from each group examined at 4 and 7 days after
injury. Wound closure was defined as complete re-epithe-
lialization from all central sections of a wound. All wounds
from both strains of mice showed partial epithelial cover-
age at 1 day after wounding. At 4 days (Figure 1), 40% of
wounds showed complete wound closure in the IL-12/IL-
23p40
-/- mice, compared with only 10% in the WT coun-
terparts. By 7 days after wounding, some 90% of wounds
in the IL-12/IL-23p40
-/- mice had healed, compared with
only 40% in the WT mice. By 10 days, all wounds in the
KO mice showed an intact epithelial layer over the wound
bed, while in the wildtype mice 1 of the 10 mice still had
yet to establish complete epithelial cover at the same time
point.
Early inflammatory response cell infiltrate in knock-out
mice
The nature of the cellular infiltrate in the healing wounds
was assessed using flow cytometry using markers for
macrophages, neutrophils and CD31 positive cells (Figure
2). More infiltrating neutrophils were detected 1 day after
wounding in the KO mice, however the increase did not
reach statistical significance. KO mice displayed an
increase in macrophage numbers from 0 to 7 days after
injury, with almost double at 1 day after wounding com-
pared to WT mice (11% vs. 6.6%, respectively). There
Table 1 Percentage of complete wound closure in IL-12/
23p40
-/- and C57BL/6J mice.
Time after wounding Day 1 Day 4 Day 7 Day 10
IL-12/23p40
-/- 0% 40%** 90%** 100%
C57BL/6J 0% 10% 40% 80%
Wounds from the IL-12/23p40
-/- mice healed significantly faster at days 4 and
7 compared to C57BL/6J control mice. Log-rank (Mantel-Cox) Test, p = 0.002**;
n = 10 per strain, per time point.
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KO mice, but this decreased to baseline levels by day 7.
An opposite trend was seen in the WT counterparts,
where the number of CD31 positive cells increased from
day 1 to day 7 after wounding. Overall there was a con-
sistent trend for higher numbers of neutrophils, macro-
phages and CD31 positive cells in KO wounds.
Analysis of the neutrophil and macrophage infiltrate
in the wounds using immunohistochemistry confirmed
the trend of a greater inflammatory infiltrate in the KO
mice There was a trend for more infiltrating neutrophils
in KO mice 1 day after wounding compared to wildtype
mice with the reverse trend at 4 days after wounding.
Likewise, there was a trend for more infiltrating macro-
phages at days 0, 1 and 4 in the KO mice compared
with controls, which was in keeping with the flow cyto-
metry data.
Early upregulation mRNA of inflammatory and immune
markers
The summary of fold changes of all genes studied is
provided in additional file 1, table S1. Genes of interest
a r es h o w ni nT a b l e2 .T h e r ew e re significant increased
levels (more than 2 fold increase, p < 0.05)w i t h i n2 4
hours after wounding in IL-12/IL-23p40
-/- mice for the
chemokines; endothelial derived neutrophil attractant
(ENA78), macrophage inflammatory protein-2 alpha
(MIP-2a), monocyte chemoattractant protein (MCP)-1
and MCP-3. MCP-1 and MCP-3 mRNA induction
occurred from day 1 after wounding and peaked at day
4. The early induction of these chemokines was followed
by reduction to baseline levels by day 7. In addition, the
pro-inflammatory cytokines IL-1b a n dI L - 6s h o w e da
marked increase 1 day after wounding in KO mice, with
fold increases of 953× and 247× respectively, compared
to 165× and 20× in the WT counterparts (Table 2).
This rapid increase was followed by an equally rapid
return to baseline levels by day 4. Overall, the data sup-
port an early inflammatory response to wounding in the
KO mice compared to WT mice.
Early establishment of angiogenesis in IL-12/IL-23p40
-/-
mice
Anti-CD31 antibody was used to estimate the extent of
angiogenesis. A significantly larger area of vasculariza-
tion over the wound bed was demonstrated in KO mice
Figure 1 Day 4 after wounding, complete wound closure was observed in the IL-12/23p40
-/- mice (Figure 1A and 1B) compared with open
wounds (incomplete epithelialization) in the control group. Original magnification ×4 (Figures 1A and 1C) and ×10 (Figures 1B and 1D).
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4.6; p = 0.026) (Figure 3). Anti-Factor VIII was used to
confirm areas of angiogenesis. The results from Factor
VIII immunostaining were consistent with those for
CD31,
with a greater area of staining at day 1 in the KO mice
than in the WT mice (25.3 ± 3.0 vs. 9.7 ± 1.2;p=
0.008) (Figure 4). These two observations complemented
the up-regulation of mRNA levels for VEGF-A in the
KO group which was seen 2 hours after wounding com-
pared to the WT mice. By 7 days after wounding,
VEGF-A levels in the KO mice had returned to baseline,
b u tt h e yr e m a i n e de l e v a t e di nt h eW Tm i c e(p < 0.05)
(Figure 5A).
Cell counts for CD31 showed a larger infiltrate at day
1 in the KO mice compared to the WT mice (Figure
5B). There was a statistically significant difference in
CD31 positive stained cells 4 days after wounding. The
control group had an increasingly larger infiltrate, while
there was a decreased number of CD31
+ cell infiltrate in
the KO group (p = 0.002). This observation between the
two strains of mice at the same time point was clearly
visible at the base of the wounds, adjacent to the wound
edges. In the KO mice, the base of the wound displayed
a more organized granulation tissue compartment com-
pared to the WT mice where numerous blood vessels
are scattered around a largely unorganized matrix
compartment.
Discussion
Research into wound healing can help decipher the
intricate molecular and cellular mechanisms involved in
repair, and can also provide clues to novel therapeutic
targets for promoting regenerative healing. This preli-
minary study investigated the effect of deficiency of IL-
12 and IL-23 in wound healing using cytokine KO mice.
This study is the first to demonstrate that IL-12/IL-
23p40
-/- mice display significant acceleration of healing
of oral mucosal wounds compared to controls. The
accelerated wound closure likely occurs through multi-
ple mechanisms. Firstly, there is a small influence on
neutrophil infiltration at day 1 after wounding in the
KO mice but is likely to be of lesser importance than
the enhanced influx of macrophages which follows it.
IL- 12/IL-23p40 is produced by both neutrophils and
macrophages as well as by other inflammatory cells, and
Figure 2 Percentage of neutrophils (A), macrophages (B) and
CD31 positive cells (C) detected in healing wounds of IL-12/IL-
23p40
-/- mice compared with C57BL/6J per 10,000 events.
Table 2 Fold changes of genes of interest during the
time-course of a healing wound in IL-12/23p40
-/- and
C57BL/6J mice.
Gene of Interest Strain of Mouse Fold-Change
Day 1 Day 4 Day 7
IL-12/IL-23p40 71.59 9.62 7.92
MCP-1 C57BL/6J 27.21 6.02 5.16
IL-12/IL-23p40 128.6 17.63 11.77
MCP-3 C57BL/6J 58.07 8.76 8.55
IL-12/IL-23p40 11235 788.3 1104
MIP-2 C57BL/6J 2073 763.9 274.5
IL-12/IL-23p40 3028 1296 1523
ENA-78 C57BL/6J 974.4 2037 821.8
IL-12/IL-23p40 953.9 86.42 215.6
IL-1b C57BL/6J 165.0 115.7 59.11
IL-12/IL-23p40 247.1 24.59 14.54
IL-6 C57BL/6J 20.84 35.77 13.76
Expression profile of chemokines (MCP-1, MCP-3, MIP-2 and ENA-78) and
cytokines (IL-1b and IL-6) seen in the IL-12/IL-23p40
-/- mice parallel the early
recruitment of inflammatory cells and early establishment of an inflammatory
response. Fold-changes were calculated using C57BL/6J unwounded samples
as control group. Student’s t-test, p value <0.05; n = 2 per strain, per time
point.
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its effects are less potent than other macrophage che-
moattractants such as MIP-1, MCP-1 and RANTES
[27-29]. Because of redundancy, the absence of the IL-
12/IL-23p40 molecule in KO mice may elicit a greater
compensatory response from other pathways which
enhance the recruitment of macrophages. Together, the
increased infiltration of neutrophils and macrophages
appears to have a favorable effect on the progression of
the healing process.
Preliminary analysis of mRNA levels of chemokines
which are chemoattractants for neutrophils and macro-
phages partially explains the trend for a larger inflam-
matory infiltrate in the KO group. Both GRO-1 and
ENA-78 are released by degranulating platelets and
initiate neutrophil recruitment into the wound bed
[30-32]. The early induction of these chemokines after
wounding in IL-12/IL-23p40 KO mice would enhance
neutrophil influx. Likewise, enhanced expression of
MIP-3a and MDC may also contribute to earlier recruit-
ment of macrophages in the KO mice. MIP-3a and
MDC mediated recruitment of macrophages augments
the inflammatory response and promotes debridement
during wound healing [27,33]. In addition, the chemo-
kines GRO-1, MIP-2 and ENA-78 mediate angiogenesis
and epithelialization [33,34]. Early induction of such
chemokines would create an environment conducive to
accelerated epithelialization and formation of capillaries
in the healing wound.
Polymorphonuclear leukocytes and macrophages as
well as some resident fibroblasts and keratinocytes
secrete IL-1b and IL-6 in a healing wound, and mRNA
expression of these cytokines is up-regulated during the
inflammatory phase of healing [35-37]. Both IL-1b and
IL-6 showed rapid and marked increase within 1 day of
wounding in KO mice. IL-1 stimulates keratinocyte
migration and proliferation, and enhances fibroblast
secretion of fibroblast growth factor (FGF)-7 [32]. IL-6
is chemoattractive to neutrophils, and a potent mitogen
for keratinocytes. The marked upregulation of IL-1b and
IL-6 provides evidence of an early inflammatory
response, but most importantly this was followed by
rapid return to baseline levels which demonstrate a
robust but controlled inflammatory response. The
simultaneous presence of IL-6 and IL-1 within 24 hours
after wounding would increase neutrophil infiltration
into the wound site and promote epithelial closure, and
thereby contribute to accelerated healing [32].
Early induction of VEGF-A is a further mechanism
which would be operating in KO mice. This growth factor
promotes the early events in angiogenesis, particularly
endothelial cell migration and proliferation [38-44], which
in turn leads to the formation of granulation tissue. Angio-
genesis is essential for effective healing, and inhibition of
angiogenesis delays or impairs wound healing [45,46]. In
the IL-12/IL-23p40
-/- mice, angiogenesis was well estab-
lished by the first day after wounding, as demonstrated by
staining for CD31 and Factor VIII in tissue sections, and
by analysis of cell homogenates for CD31 positive cells.
The earlier establishment of an angiogenic response in the
KO mice is implicated as a major mechanism which
underpins accelerated wound healing.
As mentioned previously, the influence of IL-12 on
angiogenesis is mediated through IFN-g [14], however
recent findings support an alternative pathway. The pre-
sence of IL-12 has been associated with down-regulation
of MMP-9 [15,47-49] which directly affects endothelial
cell function and inhibits angiogenesis [49]. MMP-9
facilitates angiogenesis by breaking down the ECM,
Figure 3 Analysis of angiogenesis at wound sites. Sections were
stained with anti-CD31 antibody. Immunohistochemical sections 1
day after wounding in IL-12/IL-23p40
-/- mice (A) and C57BL/6J (B).
The area of CD31
+ site was significantly larger in the KO group
compared to control group 1 day after wounding (55.3 ± 6.7 vs.
27.3 ± 4.6; p = 0.026). The diagonal cross overlaid on the slide
image shows approximately areas of CD31
+ sites.
Matias et al. Journal of Inflammation 2011, 8:39
http://www.journal-inflammation.com/content/8/1/39
Page 7 of 11allowing endothelial cells to migrate, proliferate and dif-
ferentiate into new capillaries [50]. Additionally, MMP-9
may further support this process by releasing matrix-
sequestrated angiogenic growth factors, such as PDGF
[51]. Recently, evidence of a direct link between MMP-9
and VEGF-induced angiogenesis has also been demon-
strated [52]. The findings from this study infer that defi-
ciency of IL-12 appears to be influential in facilitating
the establishment of an early angiogenic response to
wounding. Whether this effect is mediated through IFN-
g or through the downstream effect of MMP-9 on
angiogenesis is yet to be determined. Nevertheless, the
reciprocal relationship between IL-12, MMP-9 and
VEGF warrants further investigation in light of new
findings in this study.
Taken together, the expression profiles for chemokines
and cytokines in this preliminary analysis in IL-12/IL-
23p40
-/- mice parallel the key events of early recruitment
of phagocytes, enhanced epithelialization, and early estab-
lishment of angiogenesis which together contribute to the
favorable healing phenotype observed. The next aspect of
this study would involve further investigation and
confirmation of causal roles of mediators identified includ-
ing specific chemokines, as well as facilitators of angiogen-
esis. In addition, experiments including single KO mice
lacking only IL-12 or IL-23 would be used to distinguish
the contribution of this distinct cytokines to the acceler-
ated healing phenotype observed in this study. Apart from
using these mediators as potential novel therapeutic agents
of repair, this study also provides a platform to investigate
related chronic conditions such as impaired healing in dia-
betics, as well as cutaneous conditions such as psoriasis.
The relationship of IL-12 and IL-23 is of particular interest
in light of recent publications that have reported IL-12p40
polymorphism affecting age of onset and deterioration of
glycemic control in certain racial groups [53,54]. Apart
from this genetic link between diabetes and IL-12/IL-
23p40, immunological studies have demonstrated that
therapies enhancing BTLA-negative co-signalling may be
a potential therapeutic target in treating autoimmune dia-
betes [55]. Moreover, genetic variations that encode subu-
nits of cytokines (IL-12B, IL-23A) or cytokine receptors
(IL-23R) have been associated with immune disorders
such as psoriasis and psoriatic co-morbidities, including
Figure 4 Analysis of angiogenesis at wound sites. Figures 4A and 4B show immunohistochemical sections 1 day after wounding in IL-12/IL-
23p40
-/- mice. Sections were stained with anti-Factor VIII. Original magnification ×4 and ×20, respectively. Figures 4C and 4D show sections of
C57BL/6J wounds 1 day after wounding (stained with anti-Factor VIII). Original magnification ×4 and ×20, respectively. There was a significantly
larger Factor VIII positive area in the knockout mice compared to wild-type controls (t-test; p value 0.008).
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Page 8 of 11Crohn’s disease and diabetes[56]. In summary, there is
great scope in exploring the impact of IL-12/IL-23p40 and
wound healing and its relation to several chronic diseases.
Additional material
Additional file 1: Table S1 - Summary of fold changes in mRNA of
genes of interest. This file contains the summary of fold changes in
mRNA of all genes of interest studied. The fold changes upregulated ≥3
fold are enumerated in green, fold changes downregulated ≥3 are
enumerated in red, while statistical significance ≤0.05 is enumerated in
blue.
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